3D brain imaging technology earns FDA approval

An imaging technology called RAPID CTA that enables 3D visualization of a brain’s blood vessels has received FDA clearance, iSchemaView announced May 1.

According to a press release, RAPID CTA builds on standard CT angiograms (CTAs) by adding a colored overlay identifying brain regions with reduced blood vessel density. The tool also allows a 3D reconstruction of the vascular network so physicians can view images from multiple angles.

These brain maps—which can be produced in a few minutes—could facilitate quicker patient triage and clinical decision-making, including whether a stroke patient requires transfer to another facility.

“Many eligible stroke patients with large vessel occlusions must be quickly transferred to a comprehensive stroke center,” said Greg Albers, MD, director of the Stanford Stroke Center and cofounder of iSchemaView. “The new automated RAPID CTA tool makes it easy for community hospitals to quickly identify potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is appropriate for transfer. With the addition of CTA to RAPID’s FDA indications, hospitals and clinics of all sizes and locations can now use the platform to immediately review images from wherever they are.”

iSchemaView also holds FDA approval for other aspects of its RAPID platform, including MRI and CT perfusion solutions. The images generated with these techniques are available for physicians to view remotely from either desktop or mobile devices, according to the press release.